vimarsana.com
Home
Live Updates
Nct05580562 - Breaking News
Pages:
Latest Breaking News On - Nct05580562 - Page 1 : vimarsana.com
ONC201 Looks to Prove Efficacy in Trial For Rare H3K27M-Mutated Diffuse Midline Gliomas
The dopamine receptor D2 antagonist ONC201 is under evaluation in patients with H3K27M-mutated diffuse midline glioma in the phase 3 ACTION trial.
North carolina
United states
University of pennsylvania
University of north carolina
Stephen bagley
Ashley sumrall
Hospital of the university pennsylvania
University of north carolina chapel hill
Abramson cancer center
Atrium health carolinas medical center
Atrium health levine cancer institute
Internal medicine
Medical oncology
North carolina chapel hill
Phase studies pave
Data shows tolerable safety profile
Dr Bagley on the ACTION Trial of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas
Stephen Bagley, MD, MSCE, discusses the phase 3 ACTION trial evaluating ONC201 in H3K27M-mutant diffuse midline gliomas.
United states
Stephen bagley
University of pennsylvania hospital
Pennsylvania hospital
Penn medicine
Phase 3 action trial
Onc201 i
H3k27m mutant diffuse midline gliomas
vimarsana © 2020. All Rights Reserved.